ADARx Shares Rise in Nasdaq Debut
Shares of ADARx Pharmaceuticals rose 30% in their Nasdaq debut after raising $446.3 million in an upsized IPO. The gene therapy developer priced shares at the top of its range and secured a concurrent investment from AbbVie.
Xurve View
Perspectivas:
Xurve View
ADARx Pharmaceuticals shares rose 30% on Friday morning following an upsized $446.3 million IPO in the United States. The clinical-stage gene therapy developer priced its shares at $17 before opening at $22.10. The company sold 26.3 million shares at the top of its marketed range.
